1. Introduction

Cognitive Biomarker Governance Accountability is a proposed legal and regulatory framework for ensuring that the collection, interpretation, storage, and use of biological indicators associated with cognitive functions are lawful, scientifically reliable, transparent, fair, and subject to effective oversight.

The phrase is not, by itself, a universally recognized legal doctrine with a settled body of case law. It combines three distinct concepts:

Cognitive biomarkers: Measurable biological characteristics that may help indicate cognitive processes or neurological conditions, such as brain-wave patterns, neuroimaging findings, or certain biochemical markers.

Governance: Rules governing how these biomarkers are researched, collected, analyzed, and used in healthcare, employment, education, insurance, and other institutional settings.

Accountability: Legal responsibility for errors, discrimination, privacy violations, misuse of data, inadequate consent, and harmful decisions based on biomarker results.

The central legal question is:

Who should be legally responsible when cognitive biomarker data is used to make consequential decisions about a person's health, liberty, employment, education, insurance, or legal capacity?

The answer may involve constitutional law, medical ethics, privacy and data-protection law, professional negligence, product liability, anti-discrimination law, and administrative accountability.

2. Meaning and scope of cognitive biomarkers

EEG Testing: Brain Health Insights | Mir Neurology Maryland

A. Neurophysiological biomarkers

Examples include electroencephalography (EEG) patterns and other measurements of neural activity. They may help investigate sleep, seizures, attention, or certain neurological conditions. A measured signal does not automatically establish a person's thoughts, intentions, honesty, or decision-making capacity.

2-Minute Neuroscience: Neuroimaging

B. Neuroimaging biomarkers

MRI, functional MRI, and related imaging techniques may identify structural or functional patterns associated with particular conditions. Interpretation requires appropriate clinical context, validated methods, and recognition of uncertainty.

NfL als Biomarker-Hotspot - Neurologie - Universimed - Knowledge that matters

C. Molecular and biochemical biomarkers

Certain proteins, metabolites, and other biological measurements may assist in diagnosing or evaluating neurological diseases. Their meaning depends on the specific biomarker, the test's validation, and the intended clinical use.

A critical distinction is that a biomarker is not necessarily a direct measurement of cognition. A biological association with memory, attention, or disease does not, without additional evidence, establish intelligence, culpability, reliability, future conduct, or legal competence.

3. Core principles of governance accountability

A. Informed consent and cognitive autonomy

A person should understand what a cognitive biomarker test measures, why the data is being collected, what conclusions can reasonably be drawn, who will receive the results, and whether the information will be reused for research or commercial purposes.

Consent should not be treated as unlimited permission. Consent to a clinical test does not necessarily authorize an employer to obtain the results or a technology company to use them for targeted advertising.

For legally or clinically significant testing, safeguards should address:

Voluntary and informed participation.

The ability to refuse non-essential testing without unfair penalties.

Appropriate procedures where decision-making capacity is genuinely in question.

Additional safeguards for children and other vulnerable participants.

Withdrawal of consent where legally applicable and explanation of any limits on withdrawal.

B. Scientific validity and reliability

Governance requires distinguishing between a validated clinical test and an experimental prediction about human behaviour.

A responsible institution should establish:

Analytical validity — whether the test reliably measures what it claims to measure.

Clinical validity — whether the result is meaningfully associated with the condition or trait under investigation.

Clinical utility — whether using the result improves decisions or outcomes.

Population validity — whether the test performs adequately across relevant populations and circumstances.

A biomarker that correlates with attention in a controlled study should not automatically be used to label an employee as unproductive or a student as intellectually incapable.

C. Privacy and confidentiality

Cognitive biomarker records may reveal health conditions, neurological characteristics, or information from which sensitive mental states are inferred. Even when data does not directly record thoughts, combining it with behavioural information or artificial intelligence may create new privacy risks.

Accountable governance therefore requires data minimisation, access restrictions, appropriate security, retention limits, controlled disclosure, and remedies for misuse.

D. Non-discrimination and equality

Biomarker-based decisions may unfairly disadvantage people because of disability, age, neurological differences, socioeconomic circumstances, or limitations in the dataset used to train an algorithm.

For example, an insurer might use an inadequately validated cognitive-risk score to charge higher premiums. An employer might reject an otherwise qualified candidate because a wearable device generates a questionable fatigue or attention score.

Such decisions may engage applicable equality, disability, employment, consumer-protection, and data-protection laws. The legal outcome depends on the jurisdiction and the particular decision.

E. Explainability and the right to challenge

Where a biomarker score influences a consequential decision, the affected person should, where applicable, be able to obtain an explanation, correct inaccurate records, request human review, and challenge the decision before an appropriate authority.

An institution should not avoid responsibility by claiming that the outcome was generated by a proprietary algorithm or an external technology supplier.

4. Who is accountable?

Healthcare providers and laboratories

Responsible for professional standards, proper consent, accurate interpretation, appropriate communication of results, and confidentiality.

Developers and manufacturers

Responsible, to the extent imposed by applicable law, for reliable design, appropriate validation, truthful claims, risk management, security, and relevant product-safety obligations.

Employers, insurers, schools, and other decision-makers

Responsible for the legality of their own use of biomarker results, fair decision-making, and compliance with applicable privacy and anti-discrimination rules.

Regulators and public authorities

Responsible for exercising their statutory powers lawfully, supervising regulated activities where authorised, and providing access to applicable review and complaint mechanisms.

Accountability is therefore distributed rather than exclusive. A vendor may be responsible for a defective or misleading tool, while an employer may separately be responsible for using the tool unlawfully. Contractual allocation of responsibility does not necessarily eliminate either party's duties to affected individuals.

5. Leading case laws and their legal significance

The following cases provide established legal principles relevant to cognitive biomarker governance. They are not all direct decisions about cognitive biomarkers; rather, they supply legal standards that can be applied to analogous disputes.

Case 1. Justice K.S. Puttaswamy (Retd.) v. Union of India, (2017) 10 SCC 1

India · Supreme Court

Facts and issue: A nine-judge bench considered whether privacy is a constitutionally protected fundamental right.

Decision: The Supreme Court unanimously recognised privacy as a fundamental right protected by the Constitution, particularly under Article 21 and the freedoms in Part III. The judgment connects privacy with dignity, liberty, and individual autonomy.

Indian Kanoon+1

Application to cognitive biomarkers:

Brain-related and cognitive-health information may attract strong privacy protections.

State-mandated cognitive testing may require justification under constitutional standards.

Collection and use of such information should be assessed for legality, legitimate purpose, necessity, and proportionality.

The case provides a foundation for challenging unjustified state surveillance or intrusive uses of neurological information.

Accountability principle: A public authority should not collect or use highly sensitive cognitive data merely because technology makes it possible.

Important qualification: Puttaswamy does not establish a separate, unlimited fundamental right specifically called the “right to cognitive privacy.” Its established privacy principles may support arguments for protecting such information.

Case 2. Samira Kohli v. Dr. Prabha Manchanda, (2008) 2 SCC 1

India · Supreme Court

Facts: A patient consented to a diagnostic procedure, but the doctor performed additional major surgery without obtaining her specific consent.

Decision: The Supreme Court explained that valid medical consent must be voluntary and based on adequate information. A doctor ordinarily cannot extend consent to a materially different procedure merely because the doctor believes it would benefit the patient. The Court recognised a narrow emergency exception where delay would be unreasonable and necessary to save life or preserve health.

Indian Kanoon+1

Application to cognitive biomarkers:

Suppose a patient agrees to a neurological test for clinical diagnosis. The hospital subsequently uses the patient's data to train a commercial behavioural-prediction model without appropriate authorisation.

The case supports the broader principle that permission for one medical purpose should not automatically be treated as permission for a substantially different intervention. Whether the secondary data use is unlawful must also be assessed under the applicable privacy and research rules.

Accountability principle: Medical professionals and institutions must respect the scope of valid consent and cannot justify every unauthorised act by invoking the patient's presumed benefit.

Case 3. Z v. Finland, Application No. 22009/93, judgment of 25 February 1997

European human-rights law

Facts: The case concerned the disclosure and potential public availability of confidential medical information in criminal proceedings.

Decision: The European Court of Human Rights emphasised that confidentiality of personal medical information is fundamental to privacy under Article 8 of the European Convention on Human Rights. It found that the proposed disclosure of the applicant's identity and medical information after a limited confidentiality period was not sufficiently justified. Other investigative disclosures were assessed separately and were not all held unlawful.

HUDOC+1

Application to cognitive biomarkers:

Cognitive biomarker results could reveal sensitive neurological or mental-health information. Unnecessary disclosure to employers, insurers, journalists, or unrelated third parties may damage dignity, employment prospects, and personal relationships.

Accountability principle: Medical confidentiality requires effective safeguards, and any legally compelled disclosure must be assessed against its purpose, necessity, and proportionality.

Case 4. S. and Marper v. United Kingdom, Applications Nos. 30562/04 and 30566/04

European human-rights law

Facts: Authorities retained fingerprints, cellular samples, and DNA profiles of individuals whose criminal proceedings had ended without conviction.

Decision: In 2008, the Grand Chamber held that the blanket and indiscriminate retention at issue violated Article 8. The judgment stressed the sensitivity of biological information and the importance of safeguards and proportionate retention periods.

HUDOC+1

Application to cognitive biomarkers:

A government or private organisation should not assume that indefinitely retaining cognitive profiles is justified simply because they were lawfully collected initially.

For example, retaining a former employee's detailed neurological profile indefinitely for unspecified future risk assessment could raise serious privacy and proportionality concerns.

Accountability principle: Data retention must be justified by a legitimate purpose, appropriate safeguards, and a proportionate duration, subject to the governing legal framework.

Case 5. Canterbury v. Spence, 464 F.2d 772 (D.C. Cir. 1972)

United States · Federal Court of Appeals

Facts and decision: This influential US decision addressed a physician's obligation to disclose material risks associated with proposed medical treatment. It articulated an approach focused on the information a reasonable patient would need to make an informed choice.

Application to cognitive biomarkers: A provider offering an experimental biomarker test should explain material limitations, uncertainties, foreseeable risks, and relevant alternatives, as required by applicable law.

Accountability principle: Consent is meaningful only when the individual receives sufficient information to make an informed decision. The precise disclosure standard varies by jurisdiction.

Case 6. S. and Marper v. United Kingdom and automated profiling

Beyond its relevance to retention, the Marper judgment is important when biological data are converted into persistent profiles.

A cognitive profile may be more intrusive than an isolated clinical result when it is combined with longitudinal behavioural records, used to infer future conduct, or shared across multiple institutions.

Accountability principle: The legal assessment must consider not only the original measurement but also the inferences, secondary uses, and practical consequences enabled by the resulting profile.

These authorities collectively support privacy, consent, confidentiality, and proportionality safeguards. They do not establish that every cognitive biomarker application is unlawful or that every inference derived from biological data is legally prohibited.

Case 7. Suchita Srivastava v. Chandigarh Administration, (2009) 9 SCC 1

Facts: The case concerned a woman with an intellectual disability who became pregnant while living in a government-run institution. The authorities sought permission to terminate her pregnancy without her consent.

Decision: The Supreme Court upheld the importance of reproductive choice and personal autonomy, recognising that reproductive decisions fall within the protection of personal liberty under Article 21.

API Sci

Application: Cognitive test results or a diagnosis should not automatically deprive a person of the right to make personal decisions. Where decision-making capacity is disputed, it must be assessed in relation to the particular decision and applicable legal standards.

Accountability principle: A cognitive impairment label should not automatically substitute institutional judgment for an individual's legally protected autonomy.

6. Legal framework in India

Several Indian legal frameworks may apply to cognitive biomarker governance, depending on the circumstances.

The Digital Personal Data Protection Act, 2023: an important timing qualification

As of 2 November 2026, the DPDP Act is subject to a phased commencement schedule. The November 2025 notification brought specified institutional and administrative provisions into force immediately, while many substantive processing obligations and individual rights were scheduled for commencement 18 months later, on 14 May 2027. The relevant provision must therefore be checked before asserting that a particular duty or remedy is already operative.

E-Gazette+2

This distinction matters because it would be misleading to treat every provision of the DPDP Act as already enforceable in November 2026. Other applicable laws and constitutional protections may still be relevant.

7. Accountability in practical situations

Scenario A: Employer uses a cognitive-risk score

An employer rejects an applicant because an unvalidated algorithm predicts poor concentration.

Potential legal issues: Discrimination, unfair employment practices, inaccurate data, and lack of a rational basis for the decision.

Appropriate safeguards: Independent validation, job-related relevance, human review, a meaningful opportunity to challenge the result, and compliance with applicable employment law.

Scenario B: Hospital discloses cognitive biomarker data

A hospital shares a patient's neurological test results with a commercial partner without an adequate legal basis.

Potential legal issues: Medical confidentiality, privacy, consent, contractual duties, and applicable data-protection law.

Appropriate safeguards: Access controls, documented authority for disclosure, purpose restrictions, security measures, and an effective complaint process.

Scenario C: Court relies on a biomarker to assess culpability

A prosecutor claims that a neurological pattern proves that an accused person intended to commit an offence.

Potential legal issues: Evidentiary reliability, expert testimony, procedural fairness, and the risk of confusing a statistical association with proof of intent.

Appropriate safeguards: Scientific scrutiny, disclosure of methodological limitations, cross-examination of experts, and evaluation under the applicable rules of evidence.

Scenario D: School uses brain data to classify students

A school uses wearable devices to rank children by attention and places low-scoring students in restrictive academic tracks.

Potential legal issues: Children's privacy, consent, disability discrimination, educational fairness, and the lawfulness of the assessment method.

Appropriate safeguards: Age-appropriate protections, validated educational assessments, strict limits on data use, and a prohibition on treating experimental scores as definitive judgments of ability.

These are hypothetical applications of established legal principles, not summaries of court decisions directly involving the precise scenarios described.

8. Recommended governance and accountability framework

A robust institutional framework should include the following controls.

Pre-deployment assessment: Document the scientific evidence, intended purpose, known limitations, foreseeable harms, and groups potentially affected.

Legal and ethical authorisation: Identify the appropriate legal basis, consent requirements, research approvals, and applicable regulatory permissions before collection or deployment.

Data protection by design: Collect only necessary information, restrict access, establish retention periods, and protect data against unauthorised disclosure.

Human oversight: Require meaningful professional review before using uncertain biomarker results for consequential decisions.

Audit trails: Record who accessed the data, which model or test was used, the version of the system, the decision made, and the reasons for that decision.

Independent review: Use qualified scientific, clinical, legal, and ethics reviewers to investigate disputed or potentially harmful uses.

Effective remedies: Provide appropriate routes for correction, reconsideration, complaints, compensation where available, and regulatory or judicial review.

Periodic reassessment: Revalidate tests and models when populations, intended uses, technology, or scientific evidence change.

9. Possible causes of legal liability

Depending on the facts and jurisdiction, a harmful cognitive biomarker decision may lead to several distinct forms of liability.

These categories can overlap, but they are not interchangeable. Each has its own elements, defences, standards of proof, and remedies. A scientific error does not automatically establish negligence, and a privacy violation does not automatically establish entitlement to a particular amount of compensation.

10. Critical legal challenges

The governance of cognitive biomarkers raises several unresolved or developing questions.

Inference risk: Should information inferred about mental states receive the same protection as information directly collected from the brain?

Meaningful consent: Can consent genuinely be voluntary when an employer, school, insurer, or public authority controls access to an important opportunity?

Scientific uncertainty: What level of evidence is sufficient before a biomarker can influence a person's rights?

Commercial ownership: How should intellectual property rights in algorithms and analytical methods be balanced against individuals' privacy and access interests?

Automated decision-making: What explanation and review rights should apply when a cognitive score substantially influences a decision?

Group harm: How should institutions address systematic bias affecting populations that were inadequately represented during validation?

Mental autonomy: Should future legislation create explicit rights addressing the inference, manipulation, and commercial exploitation of cognitive states?

These questions are suitable subjects for legislative reform, judicial development, and interdisciplinary research. They should not be presented as questions already conclusively settled by the cases discussed above.

11. Conclusion

Cognitive Biomarker Governance Accountability is best understood as a proposed framework combining established legal protections with emerging challenges created by neuroscience, biotechnology, and artificial intelligence.

The most important authorities include:

Justice K.S. Puttaswamy v. Union of India — constitutional privacy and autonomy.

Samira Kohli v. Dr. Prabha Manchanda — informed consent and the limits of medical authorisation.

Z v. Finland — confidentiality of medical information.

S. and Marper v. United Kingdom — proportionality and retention of biological data.

Canterbury v. Spence — disclosure of material medical risks.

Suchita Srivastava v. Chandigarh Administration — personal autonomy and reproductive choice.

Taken together, these authorities support a central proposition: the ability to measure or predict aspects of cognition does not, by itself, confer legal authority to collect, disclose, interpret, or act upon that information without appropriate justification and safeguards.

A sound accountability system must protect individual autonomy, demand scientifically defensible evidence, identify responsible decision-makers, prevent unlawful discrimination, and provide effective remedies for misuse.

Research note: This is a general comparative-law explanation, not legal advice on a specific dispute. The cases cited establish related principles; they do not constitute a settled, standalone doctrine specifically titled “Cognitive Biomarker Governance Accountability.”